Evidence map›Paper›PMID 30242618›Full record

ArticleNeuromolecular medicine2018

Plasma β-Amyloids and Tau Proteins in Patients with Vascular Cognitive Impairment.

Sung-Chun Tang, Kai-Chien Yang, Chih-Hao Chen, Shieh-Yueh Yang, Ming-Jang Chiu, Chau-Chung Wu, Jiann-Shing Jeng

Abstract read
PubMed Publisher
In one paragraph

Article in Neuromolecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Blood-Based Biomarkers for Post-Stroke Cognitive Impairment.Current issues in molecular biology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Immunomagnetic Reduction Detects Plasma AβNeurology and therapy · 2020
    Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sung-Chun TangDepartment of Neurology, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 100, Taiwan.
Kai-Chien YangDivision of Cardiology, Departments of Internal Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 100, Taiwan.
Chih-Hao ChenDepartment of Neurology, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 100, Taiwan.
Shieh-Yueh YangMagQu Co. Ltd., Xindian District, New Taipei City, Taiwan.
Ming-Jang ChiuDepartment of Neurology, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 100, Taiwan.
Chau-Chung WuDivision of Cardiology, Departments of Internal Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 100, Taiwan. chauchungwu@ntu.edu.tw.
Jiann-Shing JengDepartment of Neurology, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 100, Taiwan. jsjeng@ntu.edu.tw.
National Taiwan University Hospital · TWNational Taiwan University · TW

Funding

Ministry of Science and Technology, Taiwan (TW) 105-2314-B-002 -001
6 · The paper itself

Abstract

Increases in plasma of β-amyloids (Aβ) and tau proteins have been noted in patients with Alzheimer's dementia (AD). Our study investigated the associations of plasma Aβ and tau proteins with dementia in stroke patients. This cross-sectional study recruited 24 controls (mean age: 67.4 ± 7.5 years, 33.3% male), 27 stroke patients without dementia (mean age: 70.7 ± 6.9 years, 60.7% male), 34 stroke patients with dementia (mean age: 78.3 ± 5.3 years, 45.5% male, Clinical Dementia Ranking (CDR): 1.46 ± 0.63), and 21 AD patients (mean age: 77.1 ± 9.1 years, 42.9% male, CDR: 1.43 ± 0.60) from a medical center. Dementia was defined as a CDR scale score of ≥ 1. The plasma levels of Aβ-40, Aβ-42, and tau were analyzed using immunomagnetic reduction. One-way analysis of variance was used to compare the differences in measured protein levels between the groups. The results indicated that plasma levels of tau and Aβ-42, but not Aβ-40, in stroke patients were significantly higher than in the controls. After adjustment for age, sex, diabetes mellitus, hypertension, and hyperlipidemia, only plasma level of Aβ-42 remained significantly higher in stroke patients with dementia than in those without dementia (OR 1.85, 1.25-2.75, p = 0.002). In summary, our results suggest that plasma Aβ-42 is a potential biomarker for dementia in stroke patients.

Indexed as

AgedAged, 80 and overAmyloid beta-PeptidesBiomarkersCase-Control StudiesCross-Sectional StudiesDementia, VascularDiabetes MellitusDyslipidemiasFemaleHumansHypertensionMaleProspective StudiesSeverity of Illness IndexStrokeAmyloid beta-PeptidesBiomarkerstau ProteinsAmyloid betaStrokeTau proteinVascular dementia

Identifiers

PMID30242618
OpenAlexW2890783624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.